China’s hemophilia B gene therapy: A challenge to pricey drugs—with caveats

Last April, China’s drug regulators greenlit Belief BioMed’s gene therapy for hemophilia B, a rare bleeding disorder. The move marks a milestone: it’s the country’s first approved gene therapy for the condition, and it directly competes with some of the world’s most expensive medicines, like Roche’s $3.5 million Hemgenix.

The approval, confirmed by Endpoints News, signals China’s push to address unmet medical needs with domestically developed advanced therapies. Hemophilia B, caused by a deficiency in clotting factor IX, currently relies on lifelong infusions or prohibitively priced one-time treatments. Belief BioMed’s therapy uses an adeno-associated virus (AAV) vector to deliver a functional copy of the F9 gene, aiming for durable factor IX production.

Yet what the approval doesn’t clarify is critical: pricing and long-term durability. While early signals suggest the therapy could undercut Western alternatives, no official cost has been disclosed. Nor has peer-reviewed data on its sustained efficacy beyond regulatory trials—standard for gene therapies, where effects can wane over years.

The regulatory status here is clear—this is a full approval, not an accelerated or conditional nod. But the clinical relevance for patients today depends on two unresolved factors. First, access: China’s national reimbursement system has yet to include gene therapies, leaving affordability in question. Second, real-world performance. The trial data underpinning approval, while sufficient for regulators, involved a limited sample size—a common constraint in rare-disease studies.

What we don’t know outweighs the hype. There’s speculation that Belief BioMed’s therapy may avoid the liver toxicity seen in some AAV-based treatments, but without head-to-head comparisons or long-term registries, that’s unproven. The company has planned post-marketing studies, yet their scope and transparency remain undefined.

For now, this is a step forward in expanding options, not a paradigm shift. The real signal isn’t the approval itself—it’s whether China can balance innovation with the practical demands of cost and durability, where even approved gene therapies often stumble.